The Cell2Cure core technology has been granted patent rights in Canada

As of the 18th of September 2023, the patent secures Cell2Cure’s technological concept for industrial production, upscaling, and distribution of allogeneic adipose tissue-derived mesenchymal stromal/stem cell product (ASCs) products has been granted in Canada (Patent number: 3000912).

The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has previously been granted in Europe (19 European PCT countries) year 2020: Publication number EP3365432B1, and in Australia 2022: Patent number: 2016342387. The priority date is October 2016.

Applications are still pending in China, Hong Kong, Japan, The Republic of Korea and in USA. We look forward to further strengthening of our intellectual property position for our technology.